ArticleFrontiers in oncology2026
Multiparametric MRI radiomics integrating Arterial Spin Labeling, Quantitative Susceptibility Mapping, and Amide Proton Transfer imaging for differentiating glioma recurrence from post-treatment response.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Using multimodal MRI, we developed a predictive model for identifying glioma recurrence and treatment response. Methods: Clinical data were retrospectively collected on 274 patients with gliomas following surgery. All patients underwent the MRI scan, including Contrast-enhanced T1 Weighted Imaging (CE-T1WI), Arterial Spin Labeling (ASL), Amide Proton Transfer Weighted (APTW) imaging, Quantitative Susceptibility Mapping (QSM), and Diffusion-Weighted Imaging (DWI). The radiomics features extracted from these images were used to construct five single sequence models, one combination model, and a Nomogram, aiming to compare the performance of various models in recognizing glioma recurrence and treatment response. Results: As a result of combining age, maximum tumor diameter, and IDH1 genotype, a clinical model was constructed, and the area under the curve (AUC) value in the training cohort was 0.748, validation cohort was 0.721 and temporal test cohort was 0.706. The AUC for the five single-sequence models ranged from 0.781-0.899 in the training cohort, from 0.705-0.789 in the validation cohort and from 0.708-0.828 in temporal test cohort. The AUC of the combined model was 0.927, 0.934 and 0.968 in the training cohort, validation cohort and temporal test cohort, respectively. The AUC of the nomogram was 0.983 in the training cohort, 0.958 in the validation cohort and 0.972 in the temporal test cohort. The combination and nomogram models outperformed the clinical and single-sequence models. Conclusions: The combined radiomics model and nomogram showed improved performance in differentiating glioma recurrence from response to treatment compared with the single-sequence models. The nomogram showed discrimination comparable to that of the combined model and may provide additional clinical value for individualized assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.